Loading...
TYME logo

Tyme Technologies, Inc.NasdaqCM:TYME Aktienübersicht

Marktkapitalisierung US$53.5m
Aktienkurs
n/a
Mein Marktwert
n/v
1Y-69.8%
7D26.9%
1D
Wert des Portfolios
​
Siehe

Tyme Technologies, Inc.

NasdaqCM:TYME Lagerbericht

Marktkapitalisierung: US$53.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tyme Technologies (TYME) Aktienübersicht

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Mehr Details

TYME grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung1/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit6/6
Dividenden0/6

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 6.9% pro Jahr zurückgegangen

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Hat keine nennenswerte Marktkapitalisierung ($54M)

Signifikante Insiderverkäufe in den letzten 3 Monaten

+ 1 mehr Risiko

TYME Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Tyme Technologies, Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Tyme Technologies
Historische Aktienkurse
Aktueller AktienkursUS$0.31
52-Wochen-HochUS$1.14
52-Wochen-TiefUS$0.22
Beta0.92
1 Monat Veränderung-6.70%
3 Monate Veränderung15.07%
1 Jahr Veränderung-69.84%
3 Jahre Veränderung-82.04%
5 Jahre Veränderung-94.16%
Veränderung seit IPO-94.08%

Aktuelle Nachrichten und Updates

Seeking Alpha • Sep 15

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Shareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
Analyseartikel • Aug 05

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05

TYME stock surges on merger agreement and Syros Pharmaceuticals

Development stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.

Recent updates

Seeking Alpha • Sep 15

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Shareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
Analyseartikel • Aug 05

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05

TYME stock surges on merger agreement and Syros Pharmaceuticals

Development stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.
Analyseartikel • Mar 19

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 07

Tyme Technologies Offers Incredible Risk-Reward

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.
Analyseartikel • Nov 19

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 27

Tyme Technologies: The Market Missed The Bullish Memo

Tyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.
Analyseartikel • Jul 19

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Mar 26

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyseartikel • Feb 19

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...
Analyseartikel • Feb 02

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...
Analyseartikel • Dec 16

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...
Analyseartikel • Dec 09

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Aktionärsrenditen

TYMEUS BiotechsUS Markt
7D26.9%1.3%1.4%
1Y-69.8%31.4%25.7%

Rendite im Vergleich zur Industrie: TYME unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 31.4% erzielte.

Rendite vs. Markt: TYME hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.7 erzielte.

Preisvolatilität

Is TYME's price volatile compared to industry and market?
TYME volatility
TYME Average Weekly Movement12.1%
Biotechs Industry Average Movement10.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: TYME hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: TYMEDie wöchentliche Volatilität (12%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
201113Richie Cunninghamwww.tymeinc.com

Tyme Technologies, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Tyme Technologies im Vergleich zum Marktanteil des Unternehmens?
TYME grundlegende Statistiken
MarktanteilUS$53.50m
Gewinn(TTM)-US$24.19m
Umsatz(TTM)n/a
0.0x
Kurs-Umsatz-Verhältnis
-2.2x
Kurs-Gewinn-Verhältnis

Ist TYME zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
TYME Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$0
Kosten der EinnahmenUS$0
BruttogewinnUS$0
Sonstige AusgabenUS$24.19m
Gewinn-US$24.19m

Zuletzt gemeldete Gewinne

Jun 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-0.14
Bruttomarge0.00%
Nettogewinnspanne0.00%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich TYME auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2022/09/16 17:39
Aktienkurs zum Tagesende2022/09/16 00:00
Gewinne2022/06/30
Jährliche Einnahmen2022/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Tyme Technologies, Inc. wird von 3 Analysten beobachtet. dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Arlinda LeeCanaccord Genuity
Joshua SchimmerEvercore ISI
Swayampakula RamakanthH.C. Wainwright & Co.